Disclaimer:
For research use only. Not for human consumption. Intended for laboratory-based studies by qualified professionals. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
 
Overview:
IGF-1 LR3 is a recombinant analog of human insulin-like growth factor-1 (IGF-1) engineered for enhanced stability and bioactivity in research settings. With an extended half-life compared to native IGF-1, this peptide is studied for its ability to promote cellular growth, differentiation, and protein synthesis, making it a central molecule in muscle, metabolic, and regenerative research.
Mechanism of Action:
IGF-1 LR3 functions as an anabolic signaling peptide that binds to the IGF-1 receptor (IGF-1R) and insulin receptor substrate pathways, activating PI3K–Akt and MAPK signaling cascades. These pathways regulate cellular proliferation, tissue repair, and glucose metabolism. The LR3 modification—substitution of an arginine at position 3 and an extended 13-amino-acid N-terminus—prevents binding to IGF-binding proteins, significantly prolonging its half-life and amplifying its biological activity.
Research Highlights:
Shown to stimulate muscle cell growth, differentiation, and recovery in vitro and in vivo studies.
Studied for roles in nerve regeneration, wound healing, and tissue remodeling.
Demonstrated increased nutrient transport, glucose uptake, and protein synthesis in metabolic models.
Commonly used in studies exploring growth hormone and IGF-axis regulation.
Specifications:
Form: Lyophilized powder (research-grade)
Purity: ≥98% (HPLC-tested)
Storage: Store at 2–8 °C, protected from light and moisture.